Rejuveron is a biotech startup that focuses on developing therapies to combat the effects of aging. The company operates in the healthcare market, specifically in the field of drug discovery and development. Its primary clients are individuals seeking to age better and live longer.

Rejuveron's business model revolves around creating a pipeline of breakthrough therapeutics that address the hallmarks of aging. These include DNA damage and mutation, senescent cells, telomere shortening, deregulated nutrient sensing, mitochondrial dysfunction, and stem cell exhaustion.

As cells age, their DNA accumulates damage and mutations, and their repair mechanisms start to fail. This promotes aging and disease. Senescent cells, or "zombie cells," are cells that should have died but instead stay alive and negatively affect other cells, causing associated diseases. Rejuveron aims to prevent the accumulation of these cells.

Telomeres, the ends of our chromosomes, get shorter as cells divide, causing cells to age and stop functioning properly. High metabolic activity can stress cells and cause them to age, but when nutrients are limited, cells enter a regenerative mode, which can increase lifespan. Rejuveron is working on mimicking this process to increase health and lifespan in humans.

Mitochondria, the powerhouse of cells, build up oxidative stress and mutations with age, leading to cellular dysfunction and aging. Additionally, stem cells lose their ability to differentiate and replace cells throughout the body as we age, leading to a weak immune system. Rejuveron is developing therapies to address these issues.

Keywords: Biotech, Aging, Therapies, Drug Discovery, Senescent Cells, Telomeres, Deregulated Nutrient Sensing, Mitochondrial Dysfunction, Stem Cell Exhaustion, Healthcare Market.